Subsidiaries of North China Pharmaceutical (600812.SH) passed the drug GMP compliance inspection.

North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. (referred to as "Xiantai Company"), has received a "Drug GMP Compliance Inspection Notification" issued by the Hebei Provincial Drug Administration (Ji Drug Admin Chemical Pharmaceutical (2025) No. 17). The inspection scope includes sterile raw materials (sodium ampicillin, production line in workshop 809); raw materials (amoxicillin, production line 1 in workshop 801, production line in workshop 806); raw materials (amoxicillin (regranulate), production line in workshop 806). It is reported that the Xiantai Company has obtained the "Drug GMP Compliance Inspection Notification" issued by the Hebei Provincial Drug Administration, indicating that Xiantai Company is now able to produce and market the raw material sodium ampicillin, further enriching its product system and meeting market demand. At the same time, the production lines related to amoxicillin and amoxicillin (regranulate) meet GMP requirements and can continue production and marketing.